Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

LTRN - Lantern Pharma Inc


IEX Last Trade
3.97
-0.070   -1.763%

Share volume: 26,057
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$4.04
-0.07
-1.73%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
24%
Profitability 25%
Dept financing 5%
Liquidity 50%
Performance 20%
Company vs Stock growth
vs
Performance
5 Days
-12.04%
1 Month
-8.09%
3 Months
-35.08%
6 Months
-19.80%
1 Year
-13.71%
2 Year
-22.68%
Key data
Stock price
$3.97
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$2.38 - $10.77
52 WEEK CHANGE
-$0.12
MARKET CAP 
44.028 M
YIELD 
N/A
SHARES OUTSTANDING 
10.765 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
BETA 
1.54
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$50,053
AVERAGE 30 VOLUME 
$61,437
Company detail
CEO:
Region: US
Website: lanternpharma.com
Employees: 25
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

lantern pharma is leading a wave of innovation in cancer treatment that we believe will bring the best therapies to patients who are most likely to respond. we are pioneering precision medicine approach to cancer by tailoring promising drug programs to the right patients. our approach is to use biomarker based genetic screening to identify and treat patients that would benefit most from our drugs. we believe this approach will reduce the cost of development and increase the speed to market. our strategy is to acquire or partner with promising drug and diagnostic companies to move forward promising personalized medicine programs for cancer patients.

Recent news